Kennedy Capital Management’s Rapport Therapeutics RAPP Stock Holding History
Bought
Maintained
Sold
Other funds holding RAPP
Kennedy Capital Management's RAPP Position: Q3 2026 in Review
Kennedy Capital Management increased its Rapport Therapeutics (RAPP) stake by 0.45% in Q3 2026, buying an estimated $48.2K and bringing the position to 251,912 shares worth $8.46M. The position accounts for 0.16% of the portfolio, ranked #214.
Kennedy Capital Management first reported a position in RAPP in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.5M in Q2 2026. 169 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.
- Kennedy Capital Management held 251,912 shares of Rapport Therapeutics worth $8.46M as of Q3 2026.
- Kennedy Capital Management bought 1,117 Rapport Therapeutics shares in Q3 2026, an estimated $48.2K.
- Rapport Therapeutics made up 0.16% of Kennedy Capital Management's portfolio in Q3 2026, its #214 holding.
- Kennedy Capital Management first reported a position in Rapport Therapeutics in Q2 2025 and has held it in 5 quarters since.
- Kennedy Capital Management's Rapport Therapeutics position peaked at $10.5M in Q2 2026.
- 169 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.
Based on Kennedy Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.